• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Frequency Therapeutics Inc.

    11/13/23 4:30:58 PM ET
    $FREQ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FREQ alert in real time by email
    SC 13G 1 d594980dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934*

    (Amendment No. )

     

     

    Korro Bio, Inc.

    (Name of Issuer)

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

    500946108

    (CUSIP Number)

    November 3, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 500946108    13 G

     

     1   

     NAMES OF REPORTING PERSONS

     

     Invus Public Equities, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Bermuda

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     418,605

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     418,605

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     418,605

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     5.2%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     PN

     

    2


    CUSIP No. 500946108    13 G

     

     1   

     NAMES OF REPORTING PERSONS

     

     Invus Public Equities Advisors, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     418,605

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     418,605

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     418,605

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     5.2%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    3


    CUSIP No. 500946108    13 G

     

     1   

     NAMES OF REPORTING PERSONS

     

     Artal International S.C.A.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Luxembourg

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     418,605

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     418,605

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     418,605

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     5.2%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    4


    CUSIP No. 500946108    13 G

     

     1   

     NAMES OF REPORTING PERSONS

     

     Artal International Management S.A.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Luxembourg

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     418,605

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     418,605

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     418,605

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     5.2%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    5


    CUSIP No. 500946108    13 G

     

     1   

     NAMES OF REPORTING PERSONS

     

     Artal Group S.A.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Luxembourg

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     418,605

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     418,605

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     418,605

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     5.2%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    6


    CUSIP No. 500946108    13 G

     

     1   

     NAMES OF REPORTING PERSONS

     

     Westend S.A.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Luxembourg

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     418,605

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     418,605

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     418,605

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     5.2%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    7


    CUSIP No. 500946108    13 G

     

     1   

     NAMES OF REPORTING PERSONS

     

     Stichting Administratiekantoor Westend

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     The Netherlands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     418,605

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     418,605

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     418,605

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     5.2%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    8


    CUSIP No. 500946108    13 G

     

     1   

     NAMES OF REPORTING PERSONS

     

     Mr. Amaury Wittouck

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Belgium

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     418,605

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     418,605

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     418,605

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     5.2%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN

     

    9


    Item 1(a).

    Name of Issuer:

    Korro Bio, Inc. (the “Issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    75 Hayden Avenue, Suite 300, Lexington MA 02421

     

    Item 2(a).

    Name of Person Filing:

     

    Item 2(b).

    Address of Principal Business Office or, if none, Residence:

     

    Item 2(c).

    Citizenship:

    (i) Invus Public Equities, L.P. (“Invus Public Equities”)

    750 Lexington Avenue, 30th Floor, New York, NY 10022

    Citizenship: Bermuda limited partnership

    (ii) Invus Public Equities Advisors, LLC (“Invus PE Advisors”)

    750 Lexington Avenue, 30th Floor, New York, NY 10022

    Citizenship: Delaware limited liability company

    (iii) Artal International S.C.A. (“Artal International”)

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Luxembourg limited partnership

    (iv) Artal International Management S.A. (“Artal International Management”)

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Luxembourg société anonyme

    (v) Artal Group S.A. (“Artal Group”)

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Luxembourg société anonyme

    (vi) Westend S.A. (“Westend”)

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Luxembourg société anonyme

    (vii) Stichting Administratiekantoor Westend (the “Stichting”)

    Claude Debussylaan, 46, 1082 MD Amsterdam, The Netherlands

    Citizenship: Netherlands foundation

    (viii) Mr. Amaury Wittouck

    Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg

    Citizenship: Belgium

    The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, $0.001 par value per share (the “Shares”)

     

    Item 2(e).

    CUSIP Number:

    500946108

     

    10


    Item 3.

    If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):

    This Item 3 is not applicable.

     

    Item 4.

    Ownership.

    (a) Amount beneficially owned:

    As of the date hereof, Invus Public Equities directly holds 418,605 Shares. Invus PE Advisors, as the general partner of Invus Public Equities, controls Invus Public Equities and, accordingly, may be deemed to beneficially own the Shares beneficially owned by Invus Public Equities. The Geneva branch of Artal International, as the managing member of Invus PE Advisors, controls Invus PE Advisors and, accordingly, may be deemed to beneficially own the Shares that Invus PE Advisors may be deemed to beneficially own. Artal International Management, as the managing partner of Artal International, controls Artal International and, accordingly, may be deemed to beneficially own the Shares that Artal International may be deemed to beneficially own. Artal Group, as the sole stockholder of Artal International Management, controls Artal International Management and, accordingly, may be deemed to beneficially own the Shares that Artal International Management may be deemed to beneficially own. Westend, as the parent company of Artal Group, controls Artal Group and, accordingly, may be deemed to beneficially own the Shares that Artal Group may be deemed to beneficially own. The Stichting, as the majority stockholder of Westend, controls Westend and, accordingly, may be deemed to beneficially own the Shares that Westend may be deemed to beneficially own. Mr. Wittouck, as the sole member of the board of the Stichting, controls the Stichting and, accordingly, may be deemed to beneficially own the Shares that the Stichting may be deemed to beneficially own.

    (b) Percent of class:

    Each of the Reporting Persons may be deemed to be the beneficial owner of the percentage of Shares listed on such Reporting Person’s cover page. Calculations of the percentage of Shares beneficially owned are based on 8,001,283 Shares outstanding as of November 3, 2023, as reported in the Issuer’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on November 6, 2023.

    (c) Number of shares as to which Invus Public Equities, Invus PE Advisors, Artal International, Artal International Management, Artal Group, Westend, the Stichting and Mr. Wittouck has:

    (i) Sole power to vote or to direct the vote:

    418,605

    (ii) Shared power to vote or to direct the vote:

    0

    (iii) Sole power to dispose or to direct the disposition of:

    418,605

    (iv) Shared power to dispose or to direct the disposition of:

    0

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6.

    Ownership of More Than Five Percent on Behalf of Another Person.

    This Item 6 is not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    This Item 7 is not applicable.

     

    11


    Item 8.

    Identification and Classification of Members of the Group.

    This Item 8 is not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    This Item 9 is not applicable.

     

    Item 10.

    Certification.

    Each of the Reporting Persons hereby makes the following certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    12


    EXHIBIT INDEX

     

    Exhibit
    Number

      

    Title

    1.    Joint Filing Agreement


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: November 13, 2023

     

    INVUS PUBLIC EQUITIES, L.P.

    By:

     

    INVUS PUBLIC EQUITIES ADVISORS,

     

    LLC, its general partner

    By:

     

    /s/ Raymond Debbane

    Name:

     

    Raymond Debbane

    Title:

     

    President

    INVUS PUBLIC EQUITIES ADVISORS, LLC

    By:

     

    /s/ Raymond Debbane

    Name:

     

    Raymond Debbane

    Title:

     

    President

    ARTAL INTERNATIONAL S.C.A.

    By:

     

    ARTAL INTERNATIONAL

     

    MANAGEMENT S.A., its managing partner

    By:

     

    /s/ Anne Goffard

    Name:

     

    Anne Goffard

    Title:

     

    Managing Director

    ARTAL INTERNATIONAL MANAGEMENT S.A.

    By:

     

    /s/ Anne Goffard

    Name:

     

    Anne Goffard

    Title:

     

    Managing Director

    ARTAL GROUP S.A.

    By:

     

    /s/ Anne Goffard

    Name:

     

    Anne Goffard

    Title:

     

    Authorized Person


    WESTEND S.A.
    By:   /s/ Anne Goffard
    Name:   Anne Goffard
    Title:   Managing Director
    STICHTING ADMINISTRATIEKANTOOR WESTEND
    By:   /s/ Amaury Wittouck
    Name:   Amaury Wittouck
    Title:   Sole Member of the Board
    MR. AMAURY WITTOUCK
    /s/ Amaury Wittouck
    Get the next $FREQ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FREQ

    DatePrice TargetRatingAnalyst
    2/15/2023Buy → Neutral
    Chardan Capital Markets
    2/13/2023Outperform → Market Perform
    Cowen
    9/22/2021$12.00 → $9.00Buy → Neutral
    Goldman Sachs
    More analyst ratings

    $FREQ
    Leadership Updates

    Live Leadership Updates

    See more
    • NorthStar Appoints Peter Pfreundschuh to Board of Managers

      NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024. Following this appointment, the Board will comprise of 9 directors, 6 of whom are non-executive. "We are pleased to welcome Pete to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Pete has deep experience in the pharmaceutical and biotechnology industry, with extensive knowledge in corporate finance, business

      4/15/24 9:00:00 AM ET
      $FREQ
      $URGN
      $VYGR
      $IMMU
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • Frequency Therapeutics Expands its Clinical Development Team, Adding Expertise in Inner Ear Physiology and Translational Science

      Company Announces Appointment of Jeffery Lichtenhan, Ph.D., to Lead Efforts in Hearing Diagnostics and Measurement; Joins Frequency from Washington University Medical School in St. Louis Frequency Therapeutics, Inc. (NASDAQ:FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the expansion of its clinical development team with the addition of Jeffery T. Lichtenhan, Ph.D., a leading expert in hearing diagnostics and measurement. Dr. Lichtenhan, an auditory neuroscientist, will help to advance the Company's hearing clinical development programs, including it

      4/13/21 7:00:00 AM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Frequency Therapeutics Appoints Kevin Franck, Ph.D., as Senior Vice President, Strategic Marketing and New Product Planning

      WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the appointment of Kevin Franck, Ph.D., as Senior Vice President of Strategic Marketing and New Product Planning. Dr. Franck will lead pre-commercial strategy and launch planning for Frequency’s clinical pipeline, including its lead program aimed at developing a restorative treatment for sensorineural hearing loss (SNHL), the most common form of hearing loss. Dr. Franck is a leader in the hearing field with 25 years of experienc

      2/8/21 7:00:00 AM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FREQ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Frequency Therapeutics downgraded by Chardan Capital Markets

      Chardan Capital Markets downgraded Frequency Therapeutics from Buy to Neutral

      2/15/23 10:23:29 AM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Frequency Therapeutics downgraded by Cowen

      Cowen downgraded Frequency Therapeutics from Outperform to Market Perform

      2/13/23 11:23:43 AM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Frequency Therapeutics downgraded by Goldman Sachs with a new price target

      Goldman Sachs downgraded Frequency Therapeutics from Buy to Neutral and set a new price target of $9.00 from $12.00 previously

      9/22/21 6:15:51 AM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FREQ
    SEC Filings

    See more
    • SEC Form 424B3 filed by Frequency Therapeutics Inc.

      424B3 - Korro Bio, Inc. (0001703647) (Filer)

      1/9/24 9:02:50 AM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Frequency Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Korro Bio, Inc. (0001703647) (Filer)

      1/9/24 9:00:59 AM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Frequency Therapeutics Inc.

      EFFECT - Korro Bio, Inc. (0001703647) (Filer)

      12/26/23 12:15:11 AM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FREQ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Frequency Therapeutics Inc. (Amendment)

      SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

      2/14/24 4:57:08 PM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Frequency Therapeutics Inc. (Amendment)

      SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

      2/14/24 3:03:45 PM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Frequency Therapeutics Inc.

      SC 13G - Korro Bio, Inc. (0001703647) (Subject)

      2/14/24 11:59:09 AM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FREQ
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NorthStar Appoints Peter Pfreundschuh to Board of Managers

      NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024. Following this appointment, the Board will comprise of 9 directors, 6 of whom are non-executive. "We are pleased to welcome Pete to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Pete has deep experience in the pharmaceutical and biotechnology industry, with extensive knowledge in corporate finance, business

      4/15/24 9:00:00 AM ET
      $FREQ
      $URGN
      $VYGR
      $IMMU
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million

      Korro will be focused on advancing a wholly owned portfolio of RNA editing programsPost-transaction cash of approximately $170 million expected to fund operations into 2026Funds multiple potentially value-creating milestones, including advancing its lead product candidate in Alpha-1 antitrypsin deficiency (AATD) through a clinical trialShares to trade on Nasdaq under the ticker "KRRO" commencing on November 6, 2023 CAMBRIDGE, Mass. and LEXINGTON, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling treatment of both r

      11/3/23 12:19:45 PM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results

      Frequency Therapeutics, Inc. (NASDAQ:FREQ) today announced business updates and financial results for the second quarter ended June 30, 2023. In July, the Company announced that it entered into a definitive merger agreement with Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines. After the anticipated consummation of the merger, the combined company will operate under Korro Bio, Inc. with a focus on the advancement of Korro Bio's portfolio of RNA editing programs and will trade on Nasdaq under the ticker symbol "KRRO." The merger is expected to close in the fourth quarter of 2023, subject to approval by Frequency Therapeutics

      8/10/23 4:01:00 PM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FREQ
    Financials

    Live finance-specific insights

    See more
    • Korro Bio and Frequency Therapeutics Announce Merger Agreement

      Merger to create a Nasdaq-listed genetic medicines company focused on advancing Korro Bio's wholly owned portfolio of RNA editing programs Lead program is a disease modifying therapy for patients with alpha-1 antitrypsin deficiency (AATD), with preclinical data showing an increase of normal A1AT protein to 85% of total protein in circulation  Combined company is expected to have cash balance of approximately $170 million at close, which is expected to provide cash runway through several value-creating milestones and into 2026 Companies to host conference call today at 8:30 a.m. ET Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel geneti

      7/14/23 6:30:00 AM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FREQ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Meyers Rachel

      4 - Korro Bio, Inc. (0001703647) (Issuer)

      11/29/23 4:55:57 PM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Meyers Rachel

      3 - Korro Bio, Inc. (0001703647) (Issuer)

      11/29/23 4:53:41 PM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lucchino David L. sold $43,573 worth of shares (1,156 units at $37.69), decreasing direct ownership by 5% to 22,150 units (SEC Form 4)

      4 - Korro Bio, Inc. (0001703647) (Issuer)

      11/27/23 8:48:47 PM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care